# CRISPR/cas13-medIated RNA TarGeting THerapy for the Treatment of Neovascular Age-related Macular Degeneration Investigator-initiated Trial (SIGHT-I)

> **NCT06031727** · EARLY_PHASE1 · RECRUITING · sponsor: **HuidaGene Therapeutics Co., Ltd.** · enrollment: 12 (estimated)

## Conditions studied

- Neovascular Age-related Macular Degeneration(nAMD)

## Interventions

- **GENETIC:** HG202

## Key facts

- **NCT ID:** NCT06031727
- **Lead sponsor:** HuidaGene Therapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-04
- **Primary completion:** 2025-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-03-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06031727

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06031727, "CRISPR/cas13-medIated RNA TarGeting THerapy for the Treatment of Neovascular Age-related Macular Degeneration Investigator-initiated Trial (SIGHT-I)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06031727. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*